Absorption, metabolism and excretion of [
- Resource Type
- Authors
- Shiyao, Xu; Dan, Tatosian; Ian, Mcintosh; Maria, Caceres; Catherine, Matthews; Koppara, Samuel; Diana, Selverian; Sanjeev, Kumar; Eunkyung, Kauh
- Source
- Xenobiotica; the fate of foreign compounds in biological systems. 48(6)
- Subject
- Adult
Male
Carbon Isotopes
Dipeptidyl-Peptidase IV Inhibitors
Administration, Oral
Humans
Heterocyclic Compounds, 2-Ring
Pyrans
- Language
- ISSN
- 1366-5928
1. Omarigliptin (MARIZEV®) is a once-weekly DPP-4 inhibitor approved in Japan for the treatment of type 2 diabetes. The objective of this study was to investigate the absorption, metabolism and excretion of omarigliptin in humans. 2. Six healthy subjects received a single oral dose of 25 mg (2.1 μCi) [